Hearts & Minds Blog

The History of LDL-Cholesterol with Dr. Antonio Gotto | Beyond Statins: The Future of Cholesterol Lowering Treatments

Tim Mayleben

President and Chief Executive Officer

Antonio M. Gotto, Jr., MD, DPhil

Dean Emeritus, Weill Cornell Medicine, and Provost for Medical Affairs Emeritus, Cornell University

In Part I and Part II of this series we explored the evolution of LDL-cholesterol: from the early days of its discovery to the statin era boom. Now, we sit down again with cardiovascular and lipids specialist, Dr. Antonio M. Gotto, Jr, for the third and final installment of “The History of LDL-Cholesterol” to get his perspective on the future of LDL-cholesterol lowering. Read on for highlights from our conversation on the evolution of cholesterol-lowering treatments; the implications of bempedoic acid-based therapies for physicians, patients… more

Reflecting on a Focused 2017 and Looking Ahead to a Transformational 2018

Tim Mayleben

President and Chief Executive Officer

The past year was marked by tremendous progress for our bempedoic acid-based franchise – perhaps most importantly the achievement of positive regulatory interactions in the U.S. together with continued over-achievement on clinical trial execution – and your support was critical to this success. As I look back on these accomplishments, I’m struck by the focus, determination, perseverance, and “grit” our team demonstrated by: Securing regulatory confirmation for the pathways to approval for an LDL-cholesterol lowering indication for both bempedoic acid and the bempedoic acid /… more

Delivering on the “Long Game”

Tim Mayleben

President and Chief Executive Officer

I was recently approached by STAT to answer, “How do you balance your long-term goals for your company with the short-term demands of investors?”  My immediate thought seemed obvious: you can’t!  In LDL-cholesterol lowering research and development, in particular, there is no way to balance our long-term timelines with the short-term orientation of many investors – and at Esperion, we don’t try to. Let me explain: clinical development programs for chronic LDL-cholesterol lowering drugs require time; long-term clinical studies of regulatory-submission quality are double-blind with… more

The Lipid Management Team Reflects on the ESC Congress; the World’s Largest Gathering of Cardiovascular Health Experts

Mary McGowan

Chief Medical Officer

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

The Lipid Management Team traveled to Barcelona last month to attend the European Society of Cardiology (ESC) Congress, the world’s largest gathering of cardiovascular health experts. To stay on the cutting-edge of the latest cardiovascular breakthroughs impacting patients with hypercholesterolemia around the world, we attended many late-breaking sessions. We also had the opportunity to discuss these recent breakthroughs with experts in the field. In addition to the overview of the bempedoic acid program presented by Prof. Stephen Nicholls MD, PhD, Professor of Cardiology and Theme… more

Important Bempedoic Acid-Based Franchise Progress Updates

Tim Mayleben

President and Chief Executive Officer

Last week was exciting for us at Esperion as we reported on tremendous progress achieved in enrolling patients for our bempedoic acid global pivotal Phase 3 program, as well as highly positive Phase 2 results from the combo plus statin study. The Lipid Management Team has been “heads down” making critical advancements for the bempedoic acid franchise both in the clinic and in conversations with regulators that will undoubtedly propel us to a successful second half of the year. First, as you may recall, we… more